Growth-hormone secretagogues & GH-axis peptides
CJC-1295 (with DAC)
Also known as CJC-1295 DAC · DAC:GRF · CJC 1295
A long-acting synthetic analogue of growth-hormone-releasing hormone (GHRH) carrying a Drug Affinity Complex that binds serum albumin.
In 60 seconds
Early clinical pharmacology only: placebo-controlled studies in healthy adults characterised its pharmacokinetics and GH/IGF-1 response in the mid-2000s; no approved medicine. The healthy-volunteer studies reported it was generally well tolerated over the study period.
- Two randomised, placebo-controlled studies in healthy adults characterised CJC-1295 pharmacokinetics and reported dose-dependent, prolonged increases in GH and IGF-1.
- Used CJC-1295 as a tool to activate the GH/IGF-1 axis and searched serum for new protein biomarkers of GH action.
- Reviews analytical methods for detecting GHRH analogues, which are prohibited by the World Anti-Doping Agency.
Mechanism
CJC-1295 is a modified GHRH(1-29) sequence acting on the pituitary GHRH receptor. Its Drug Affinity Complex (DAC) forms a covalent bond with circulating albumin, which is what extends its half-life from minutes (native GHRH) to days, producing a sustained rise in growth hormone and IGF-1 rather than a brief pulse.
Research status
Early clinical pharmacology only: placebo-controlled studies in healthy adults characterised its pharmacokinetics and GH/IGF-1 response in the mid-2000s; no approved medicine. It is monitored as a prohibited substance in anti-doping science.
Key studies
Two randomised, placebo-controlled studies in healthy adults characterised CJC-1295 pharmacokinetics and reported dose-dependent, prolonged increases in GH and IGF-1.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006 · PMID 16352683
Used CJC-1295 as a tool to activate the GH/IGF-1 axis and searched serum for new protein biomarkers of GH action.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects — Growth Horm IGF Res, 2009 · PMID 19386527
Reviews analytical methods for detecting GHRH analogues, which are prohibited by the World Anti-Doping Agency.
Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal, 2021 · PMID 34665524
A 2026 review contrasting approved peptide drugs with unapproved peptides used in sport, highlighting gaps in efficacy and safety evidence.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports Med, 2026 · PMID 41966639
Safety signals in the literature
The healthy-volunteer studies reported it was generally well tolerated over the study period. Recent sports-medicine reviews stress the absence of long-term safety data and the variable quality of unregulated product.
Legal status (South Africa)
Not a registered medicine for human use in South Africa unless SAHPRA-registered under its own name; growth-hormone secretagogues are prohibited in sport under the WADA list. Supplied, where we stock it, strictly for laboratory research.
Related compounds we stock
Not stocked yet — get notified
Tell us you want CJC-1295 (with DAC) and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add CJC-1295 (with DAC)
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is CJC-1295 (with DAC)?
A long-acting synthetic analogue of growth-hormone-releasing hormone (GHRH) carrying a Drug Affinity Complex that binds serum albumin. CJC-1295 is a modified GHRH(1-29) sequence acting on the pituitary GHRH receptor. Its Drug Affinity Complex (DAC) forms a covalent bond with circulating albumin, which is what extends its half-life from minutes (native GHRH) to days, producing a sustained rise in growth hormone and IGF-1 rather than a brief pulse.
What is the research status of CJC-1295 (with DAC)?
Early clinical pharmacology only: placebo-controlled studies in healthy adults characterised its pharmacokinetics and GH/IGF-1 response in the mid-2000s; no approved medicine. It is monitored as a prohibited substance in anti-doping science.
What safety signals are reported for CJC-1295 (with DAC)?
The healthy-volunteer studies reported it was generally well tolerated over the study period. Recent sports-medicine reviews stress the absence of long-term safety data and the variable quality of unregulated product.
Does Living Water Labs stock CJC-1295 (with DAC)?
Not at present. CJC-1295 (with DAC) is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Not a registered medicine for human use in South Africa unless SAHPRA-registered under its own name; growth-hormone secretagogues are prohibited in sport under the WADA list. Supplied, where we stock it, strictly for laboratory research.
More in GH secretagogues
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
